araag2/HINT huggingface dataset:
Clinical trial NCT00694200 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: vinorelbine, bevacizumab
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    not reached the statistical hypothesis at the interim analysis
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically- or cytologically- confirmed metastatic breast adenocarcinoma

          -  At least one previous chemotherapy regimen for metastatic breast cancer

          -  Age 18-75 years

          -  Measurable disease as defined by the presence of at least one measurable lesion
             (except bone metastases, ascites or pleural effusions)

          -  Performance status (WHO) 0-2

          -  Adequate liver function(serum bilirubin <1.5 times the upper normal limit, AST and ALT
             <2.5 times the upper normal limit in the absence of demonstrable liver metastases, or
             <5 times the upper normal limit in the presence of liver metastases), adequate renal
             function (serum creatinine <1.5 times the upper normal limit) and bone marrow
             (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function

          -  No radiation of measurable disease (except brain metastases)

          -  No progressive brain metastases according to clinical or radiological criteria

          -  No brain metastases without prior radiation therapy

          -  Written informed consent

        Exclusion Criteria:

          -  Patient unable to take oral medication

          -  Active infection

          -  History of significant cardiac disease (unstable angina, congestive heart failure,
             myocardial infarction within the previous 6 months, ventricular arrhythmias)

          -  History of stroke

          -  Anticoagulation therapy (except of low dose aspirin <325mg)

          -  Other invasive malignancy except nonmelanoma skin cancer

          -  Psychiatric illness or social situation that would preclude study compliance

          -  Pregnant or lactating women
Clinical trial NCT00530114 (phase 2, status: completed)
Conditions: end stage renal disease, chronic kidney disease, hyperphosphatemic, kidney disease
ICD codes: N18.6, I12.0, I13.11, I13.2, I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0, I12.9, N18.9, Q61.9, I12.0, D63.1, N18.1, N18.5
Drugs: amg 223, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Maintenance hemodialysis 3 times a week for at least 3 months prior to screening

          -  Single pool Kt/V at least 1.2 or urea reduction ratio at least 65%

          -  Serum phosphorus level of 3.5 to 6.5 mg/dL inclusive at screening

          -  No change(s) in type or dose of non-investigational phosphate binder(s) for at least 1
             month prior to screening

          -  Serum albumin > 3.0 mg/dL at screening

          -  If applicable, an increase in serum phosphorus of greater than or equal to 1.5 mg/dL,
             and a serum phophorous level > 5.5 mg/dL and less than or equal to 10 mg/dl during the
             washout period

          -  If applicable, stable doses (defined as no change in dose for at least 1 month prior
             to screening) of Vitamin D replacement, calcimimetic agents, or bedtime calcium
             supplements

          -  Willingness to avoid intentional changes in diet such as fasting or dieting

        Exclusion Criteria:

          -  Previous intolerance leading to discontinuation of polymer-based phosphate binder
             therapy

          -  History of noncompliance with phosphate binder therapy in the opinion of the
             investigator

          -  Anticipating or scheduled for a living related-donor kidney transplant, or a prior
             recipient of a kidney transplant

          -  Current use of antiarrhythmic or anti-seizure medication

          -  Active ethanol or drug dependence or abuse, excluding tobacco use

          -  A screening serum calcium (corrected for albumin) < 8.4 mg/dL

          -  History of bowel obstruction, swallowing disorders, severe gastrointestinal disorders,
             major gastrointestinal surgery, or gastric/duodenal ulcers within 6 months prior to
             screening

          -  Subject is pregnant, breast feeding, or is of child bearing potential and is not using
             adequate contraceptive precautions

          -  Subject is currently enrolled in or has not yet completed at least 30 days since
             ending other investigational device or drug trial(s)

          -  Subject has experienced a myocardial infarction or major surgery (excluding vascular
             access surgery) within 3 months prior to screening

          -  Clinical evidence of current malignancy and/or receiving systemic
             chemotherapy/radiotherapy with the exception of localized basal cell or squamous cell
             carcinoma of the skin and cervical intraepithelial neoplasia
Clinical trial NCT00705679 (phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: emtricitabine/tenofovir disoproxil fumarate, emtricitabine/tenofovir disoproxil fumarate placebo, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate placebo, tenofovir 1% vaginal gel, tenofovir placebo
SMILES: NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O, C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O, C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Willing to provide adequate locator information

          -  Sexually active, defined as having vaginal intercourse at least once in the 3 months
             prior to screening

          -  Agree to not participate in other research studies involving drugs, medical devices,
             or vaginal products for duration of study.

          -  Agree to use effective method of contraception. More information on this criterion can
             be found in the protocol.

        Exclusion Criteria:

          -  HIV infected

          -  Known adverse reaction to any of the study products

          -  Known adverse reaction to latex

          -  Pathologic bone fracture not related to trauma

          -  Non-therapeutic injection drug use in the 12 months prior to screening

          -  Post-exposure prophylaxis for HIV exposure within 6 months prior to enrollment

          -  Last pregnancy outcome 42 days or less prior to enrollment

          -  Gynecologic or genital procedure 42 days or less prior to enrollment

          -  Participation in any other research study involving drugs, medical devices, or vaginal
             products 30 days or less prior to enrollment

          -  Currently using spermicide, interferon or interleukin therapy, or certain medications.
             More information on this criterion can be found in the protocol.

          -  Any significant uncontrolled active or chronic disease. More information on this
             criterion can be found in the protocol.

          -  Certain abnormal laboratory values. More information on this criterion can be found in
             the protocol.

          -  Intends to become pregnant in the 24 months after enrollment

          -  Plans to relocate or travel away from the study site for more than 8 consecutive weeks
             in the 24 months after enrollment

          -  Urinary tract infection

          -  Pelvic inflammatory disease, an STI, or reproductive tract infection requiring
             treatment

          -  Grade 2 or higher pelvic exam finding

          -  Any condition that, in the opinion of the investigator, would interfere with the study

          -  Pregnant or breastfeeding
Clinical trial NCT00152841 (phase 2, status: terminated)
Conditions: crohn's disease, ulcerative colitis, mild or moderate anaemia
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919, K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: iron supplement 300-600 mg/day, vitamin e 800iu
SMILES: CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C
Reason stopped: 
    lack of patients
  
Eligibility criteria:

        Inclusion Criteria:

          -  > 18 years old

          -  diagnosed with inflammatory Bowel Disease (ulcerative colitis and Crohn's disease)

          -  with mild or moderate anaemia

        Exclusion Criteria:

          -  not diagnosed with bowel obstruction

          -  not diagnosed with short bowel syndrome

          -  not taking iron supplement or antioxidant vitamins and minerals
Clinical trial NCT00735124 (phase 2/phase 3, status: terminated)
Conditions: pain, analgesia, hernia, inguinal
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52, P04.0, K40.11, K40.41, K40.01, K40.21, K40.31, K40.91, K40.10
Drugs: gabapentin
SMILES: CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1
Reason stopped: 
    changes to surgical practices led to the loss of eligible patients
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects having elective surgery with open unilateral Inguinal herniorraphy

        Exclusion Criteria:

          -  Non elective surgery

          -  Patients currently on gabapentin therapy

          -  Patient hypersensitive to gabapentin surgery

          -  History of alcohol or drug abuse

          -  Patients who are pregnant or who are nursing
Clinical trial NCT01130272 (phase 2, status: completed)
Conditions: irritable bowel syndrome
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: eluxadoline, placebo
SMILES: COC1=CC=C(CN([C@@H](C)C2=NC(=CN2)C2=CC=CC=C2)C(=O)[C@@H](N)CC2=C(C)C=C(C=C2C)C(N)=O)C=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Patient has a diagnosis of IBS by Rome III criteria with a subtype of diarrhea

          -  Female patients must be:

          -  postmenopausal, defined as amenorrhea for at least 2 years at Prescreening,

          -  surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation,
             or otherwise be incapable of pregnancy),

          -  abstinent, or

          -  if sexually active, be practicing an effective method of birth control.

        Key Exclusion Criteria:

          -  Patient has a diagnosis of IBS by Rome III criteria with a subtype of constipation,
             mixed IBS, or unsubtyped IBS

          -  Patient has a history of inflammatory or immune-mediated gastrointestinal (GI)
             disorders including inflammatory bowel disease (ie, Crohn's disease, ulcerative
             colitis) and celiac disease

          -  Patient has a history of diverticulitis within 6 months prior to Prescreening

          -  Patient has a history of intestinal obstruction, stricture, toxic megacolon, GI
             perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic
             colitis, impaired intestinal circulation (eg, aortoiliac disease), thrombophlebitis of
             a major vein, or hypercoagulable states.

        Other protocol-specific eligibility criteria may apply.
Clinical trial NCT01025154 (phase 2, status: completed)
Conditions: acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: clofarabine, idarubicin, cytarabine
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosis of AML (World Health Organization (WHO) classification)

          2. Patients must be chemotherapy-naïve, i.e. not have received any prior cytotoxic
             chemotherapy for AML (with the exception of hydroxyurea). They could have received
             prior therapy with hypomethylating agents, targeted, or biological agents.

          3. Age 18 to 60 years.

          4. Eastern Cooperative Oncology Group (ECOG) performance status </= 2.

          5. Serum creatinine </= 1.0 mg/dL; if serum creatinine > 1.0 mg/dL, then the estimated
             glomerular filtration rate (GFR) must be > 60 mL/min/1.73m^2 as calculated by the
             Modification of Diet in Renal Disease equation where Predicted GFR
             (ml/min/1.73m^2)=186 * (serum creatinine)^-1.154 x (age in years)^-0.023 * (0.742 if
             patient is female) * (1.212 if patient is black), where SCr is serum creatinine
             measured in mg/dL. serum bilirubin </= 1.5 * upper limit of normal (ULN) (unless
             increase is due to hemolysis or a congenital disorder); serum transaminases (SGPT
             and/or SGOT) </= 2.5 * ULN.

          6. Cardiac ejection fraction >/= 45% (by either echocardiography or MUGA scan).

          7. Ability to understand and provide signed informed consent.

        Exclusion Criteria:

          1. Patients with acute promyelocytic leukemia (APL).

          2. Any coexisting medical condition that in the judgment of the treating physician is
             likely to interfere with study procedures or results.

          3. Nursing women, women of childbearing potential with positive urine pregnancy test, or
             women of childbearing potential who are not willing to maintain adequate contraception
             (such as birth control pills, intrauterine device (IUD), diaphragm, abstinence, or
             condoms by their partner) over the entire course of therapy.

          4. Active and uncontrolled infection requiring therapy with IV antibiotics or antifungal
             therapy. Prior or concurrent history of one or more opportunistic infections (e.g.,
             cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria
             other than TB).
Clinical trial NCT01442090 (phase 2, status: completed)
Conditions: renal cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: everolimus, gdc-0980
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][C@@](C)(O)C(=O)N1CCN(CC2=C(C)C3=C(S2)C(=NC(=N3)C2=CNC(=N)N=C2)N2CCOCC2)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically documented, incurable metastatic renal cell carcinoma
             with clear-cell component that progressed on or within 6 months of stopping
             VEGF-targeted therapy

          -  Disease that is measurable per Response Evaluation Criteria in Solid Tumors Version
             1.1 (RECIST v1.1)

          -  Karnofsky performance status of greater than or equal to (>=) 70 percent (%)

          -  Adequate hematologic and end organ function

          -  For female participants of childbearing potential and male participants with partners
             of childbearing potential, agreement to use two effective forms of contraception and
             to continue its use for the duration of the study

        Exclusion Criteria:

          -  Any anti-cancer therapy, including chemotherapy, biologic or other targeted therapy,
             herbal therapy, hormonal therapy, or radiotherapy, within 5 half-lives (for systemic
             agents) or 2 weeks, whichever is shorter, prior to Day 1. Certain forms of radiation
             therapy may be considered for pain palliation if participants are deriving benefit

          -  Previously established diagnosis of pulmonary fibrosis of any cause

          -  New York Heart Association (NYHA) Class II or greater congestive heart failure

          -  History of malabsorption syndrome or other condition that would interfere with enteral
             absorption

          -  Presence of positive test results for hepatitis B (hepatitis B [HB] surface antigen
             [HBsAg] and/or total HB core antibody [anti-HB-c; both tests are required]) or
             hepatitis C

          -  Known human immunodeficiency virus (HIV) infection

          -  Pregnancy, lactation, or breastfeeding

          -  Major surgical procedure or significant traumatic injury within 28 days prior to Day 1
             or anticipation of the need for major surgery during the course of study treatment

          -  Leptomeningeal disease as a manifestation of cancer

          -  History of other malignancies less than equal to <= 5 years of Day 1 except for tumors
             with a negligible risk for metastasis or death, such as adequately controlled basal
             cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the
             cervix

          -  Need for current chronic corticosteroid therapy (>= 10 milligrams [mg] of prednisone
             per day or an equivalent dose of other anti-inflammatory corticosteroids for greater
             than [>] 7 days) or use of other immunosuppressant
Clinical trial NCT01271751 (phase 2, status: completed)
Conditions: atherogenic dyslipidaemia, abdominal obesity
ICD codes: A42.1, G43.D1, I77.811, R10.815, R10.816, R10.817, R10.84
Drugs: gft505 80mg, placebo
SMILES: CSC1=CC=C(C=C1)C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or post-menopausal female.

          -  Waist circumference ≥102cm for male, ≥ 88cm for female.

          -  Atherogenic dislipidaemia inadequately controlled despite Therapeutic Lifestyle Change
             (TLC) recommendations (diet and exercise).

          -  150≤ fasting TG ≤ 600 mg/dL (1.69 ≤ fasting TG ≤ 6.78 mmol/L) at V2.

          -  Fasting HDL-C ≤ 40 mg/dL (≤ 1.03 mmol/L) for male, HDL-C ≤ 45 mg/dL (≤ 1.16 mmol/L)
             for female at V2.

        Exclusion Criteria:

          -  Body Mass Index (BMI) ≥ 40 kg/m².

          -  Blood Pressure > 160 / 95 mmHg.

          -  Type I or type II Diabetes Mellitus.
Clinical trial NCT00423332 (phase 2, status: completed)
Conditions: renal cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: cediranib, cediranib placebo
SMILES: COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1, COC1=CC2=C(C=C1OCCCN1CCCC1)N=CN=C2OC1=C(F)C2=C(NC(C)=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmation of metastatic or recurrent renal cell carcinoma

        Exclusion Criteria:

          -  Certain types of previous anti-cancer therapy for Renal Cell Carcinoma

          -  Patients with type I insulin-dependent diabetes or poorly-controlled type II
             insulin-independent diabetes

          -  Patients with a history of poorly controlled high blood pressure
Clinical trial NCT00525330 (phase 2, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: krp-104 qd drug: placebo drug: metformin, placebo drug: metformin, krp-104 bid drug: placebo drug: metformin
SMILES: [H][C@@]1(F)CN(C(=O)CNC23CCC(CC2)(CC3)C(=O)OCC)[C@@]([H])(C1)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(F)CN(C(=O)CNC23CCC(CC2)(CC3)C(=O)OCC)[C@@]([H])(C1)C#N
Eligibility criteria:

        Inclusion Criteria:

          1. Age 18 to 70 years, inclusive;

          2. Males and females of non-childbearing potential;

          3. Diagnosis of type 2 diabetes mellitus according; and

          4. On a stable dose of metformin monotherapy at randomization (can be on other oral
             therapies or naive at study entry

        Exclusion Criteria:

          1. History of type 1 diabetes mellitus or history of diabetic ketoacidosis or persistent
             hypoglycemia;

          2. History or presence of alcoholism or drug abuse

          3. Typical consumption of ≥10 drinks of alcohol weekly;

          4. Presence of any of the following conditions:

               -  Significant renal impairment (glomerular filtration rate <60 mL/min [to be
                  calculated by the central laboratory]);

               -  Diabetic retinopathy;

               -  Diabetic gastroparesis;

               -  Active liver disease (other than asymptomatic nonalcoholic fatty liver disease),
                  cirrhosis, or symptomatic gallbladder disease;

          5. Uncontrolled high blood pressure;

          6. History or evidence of cardiovascular or pulmonary disease

          7. Must meet other laboratory and Medical History clinical criteria. Please contact
             recruitment center for referrals
Clinical trial NCT01490086 (phase 2, status: completed)
Conditions: acute schizophrenia, schizoaffective disorder
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F25.9, F25.0, F25.1, F25.8
Drugs: rp5063, placebo, rp5063, rp5063, aripiprazole
SMILES: OC1=NC2=C(OC1)C=CC(OCCCCN1CCN(CC1)C1=CC=CC(Cl)=C1Cl)=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OC1=NC2=C(OC1)C=CC(OCCCCN1CCN(CC1)C1=CC=CC(Cl)=C1Cl)=C2, OC1=NC2=C(OC1)C=CC(OCCCCN1CCN(CC1)C1=CC=CC(Cl)=C1Cl)=C2, ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Patients providing informed consent prior to any study specific procedures

          -  Patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth
             Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type,
             disorganized type, catatonic type or undifferentiated type), or schizoaffective
             disorder

          -  Patients with normal physical examination, laboratory, vital signs,and
             electrocardiogram (ECG)

        Exclusion Criteria:

          -  Patients with other primary psychiatric disorders as delirium, or bipolar I or II
             disorder